Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic dermatitis ...

Please provide your email address to receive an email when new articles are posted on . The submission indicates roflumilast 0.15% for adults and children aged 6 years and older with atopic dermatitis ...

Please provide your email address to receive an email when new articles are posted on . 46.4% of children and adults receiving Vtama achieved validated IGA for atopic dermatitis response of clear or ...

Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially available Provides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be ...

Ruxolitinib cream, to be sold under the name Opzelura, is the first topical Janus kinase inhibitor cream for the treatment of atopic dermatitis. The first topical Janus kinase (JAK) inhibitor cream ...

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...

Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD) across multiple end points. According to investigators of the phase 3 studies that uncovered the findings, roflumilast ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ...